Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**UBS109** is a synthetic small molecule belonging to the class of monocarbonyl analogs of curcumin. It is designed to overcome the limitations of natural curcumin, notably improving solubility and metabolic stability. UBS109 exerts its effects primarily as a potent inhibitor of the NF-kappaB pathway, contributing to strong anticancer activity including cytotoxicity against several cancer cell lines (such as MDA-MB-231 breast cancer and Tu212 head and neck carcinoma)[1][3][4][5][7]. The compound acts by interfering with cellular signaling involved in inflammation and cancer proliferation and has been shown to inhibit osteoclastogenesis, stimulate osteoblastogenesis and mineralization, and suppress cancer cell growth and metastasis in preclinical models[3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UBS109.